Clinical Trial

TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-14.
Trial Details
NCT Number NCT07713732
Lead Sponsor Treeline Biosciences, Inc.
Conditions Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas
Enrollment 120 participants
Start Date 2026-07-25
Primary Completion 2030-08-29 (estimated)
Study Completion 2030-08-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-28